Download Files:
NU6027
$77 – $660
Products Details
Product Description
– NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with Kis of 2.5 µM and 1.3 µM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner[1][2].
Web ID
– HY-13816
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C11H17N5O2
References
– [1]Arris CE, et, al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem. 2000 Jul 27; 43(15): 2797-804.|[2]Peasland A, et, al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer. 2011 Jul 26;105(3):372-81.
CAS Number
– 220036-08-8
Molecular Weight
– 251.28
Compound Purity
– 99.35
SMILES
– NC1=NC(OCC2CCCCC2)=C(N=O)C(N)=N1
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– ATM/ATR;CDK
Isoform
– ATR;CDK1;CDK2
Pathway
– Cell Cycle/DNA Damage;PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
